Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients

International Journal of Cancer

Volumn 92, Issue 2, 2001, Pages 269-275

  Takeda, Yuichiro ^a   Kobayashi, Kunihiko ^a   Akiyama, Yoshiko ^a   Soma, Tomoyuki ^a   Handa, Satoko ^b   Kudoh, Shouji ^b   Kudo, Koichiro ^c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

Author keywords

Alkalization; Case control study; Control of defecation; Damage of intestinal mucosa; Irinotecan (CPT 11); Prevention of delayed diarrhea; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; BICARBONATE; CISPLATIN; IRINOTECAN; LOPERAMIDE; MAGNESIUM OXIDE; MORPHINE; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALKALINIZATION; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DEFECATION; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; FECES ANALYSIS; FEMALE; GRANULOCYTOPENIA; HUMAN; INTESTINE INJURY; LUNG CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PH; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTACIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW; BUFFERS; CAMPTOTHECIN; CASE-CONTROL STUDIES; DEFECATION; DIARRHEA; DIGESTIVE SYSTEM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LUNG NEOPLASMS; MAGNESIUM OXIDE; MALE; MIDDLE AGED; RISK FACTORS; SODIUM BICARBONATE; URSODEOXYCHOLIC ACID;

EID: 0035871991     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3     Document Type: Article

References (33)

1. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
2. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
3. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
4. Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily x 5 LV/FU in patients with previously untreated metastatic colorectal cancer
5. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
6. An early phase II study of CPT11: A new derivative of camptothecin for the treatment of leukemia and lymphoma
7. CPT-11, a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
8. An early phase II study of CPT-11 for gynecologic cancers
9. Docetaxel and CPT-11 for recurrent ovarian cancer - A phase II study
10. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer
11. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors
12. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
13. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study
14. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
15. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
16. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A (CYP3A) and drug interactions
17. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues
18. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution
19. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
20. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine
21. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
22. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH
23. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals
24. 14C-SN-38 to rats
25. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11
26. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride
27. Irinotecan (CPT-11) and characteristic mucosal change in the mouse ileum and cecum
28. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
29. CPT-11-induced cholinergic effects in cancer patients
30. Effect of UDCA on intracellular and biliary pH in isolated rate hepatocyte couplets and perfused livers
31. - currents in a biliary cell line
32. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: Possible role of bicarbonate transport
33. Treatment of intrahepatic cholestasis